ArrePath
Zemer is a leader in applying quantitative and computational approaches to bacterial cell biology and antibiotic development. He graduated with a bachelor’s degree from MIT in 1996, completed his graduate studies at UCSF in 2002, and joined the faculty of Princeton University in 2005 after completing a postdoc at Stanford University. At Princeton, Dr. Gitai was promoted to Associate Professor with tenure in 2012 and to Professor in 2015. In 2016 he became the Edwin Grant Conklin Distinguished Professor of Biology. He was also the Director of Graduate Studies for the Department of Molecular Biology from 2012-2018. Dr. Gitai’s achievements have been recognized by many prestigious awards, including the NIH Director’s Pioneer Award, the NIH New Innovator Award, the NIH Transformative Research Award, the Beckman Young Investigator Award, and the HFSP Young Investigator Award.
This person is not in the org chart
This person is not in any offices
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.